List of Excipients in Branded Drug THIOTHIXENE

« Back to Dashboard

Generic Drugs Containing THIOTHIXENE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	thiothixene	0378-1001	CELLULOSE, MICROCRYSTALLINE
Mylan Pharmaceuticals Inc	thiothixene	0378-1001	CROSCARMELLOSE SODIUM
Mylan Pharmaceuticals Inc	thiothixene	0378-1001	D&C RED NO. 28

What are the Most Frequently-Used Excipients in THIOTHIXENE?

# Of NDCs	Excipient
5	AMMONIA
14	CELLULOSE, MICROCRYSTALLINE
1	COLLOIDAL SILICON DIOXIDE

Thiothixene Excipient Strategy and Commercial Opportunities

Last updated: September 28, 2026

Thiothixene is an established oral antipsychotic with limited remaining intellectual-property protection and a fragmented generic market. The strongest commercial opportunities are not conventional generic capsules alone. They are differentiated oral formulations that improve administration, reduce excipient-related intolerance, support adherence, or serve institutional and specialty-care channels.

What is the commercial status of thiothixene?

Thiothixene hydrochloride is a first-generation thioxanthene antipsychotic indicated for schizophrenia. The former brand, Navane, has been discontinued, while generic thiothixene capsules remain the relevant U.S. product category.[1,2]

Attribute	Assessment
Active ingredient	Thiothixene hydrochloride
Therapeutic class	Typical antipsychotic; thioxanthene derivative
Primary indication	Schizophrenia
U.S. dosage form	Immediate-release oral capsules
Common strengths	1 mg, 2 mg, 5 mg, 10 mg, and 20 mg capsules, depending on manufacturer
Reference brand	Navane
Regulatory pathway for standard generic	Abbreviated New Drug Application, or ANDA
Biologic status	Not a biologic
Biosimilar exposure	None
Market structure	Generic, low-volume, manufacturer-dependent
Main commercial constraints	Small patient population, low reimbursement, psychiatric safety monitoring, limited prescriber demand

Thiothixene competes with haloperidol, fluphenazine, perphenazine, chlorpromazine, risperidone, olanzapine, quetiapine, and other antipsychotics. Atypical antipsychotics generally have greater commercial scale because of broader prescribing and more favorable tolerability perceptions.

What patents protect thiothixene?

The original thiothixene patent estate is no longer a material barrier to ordinary generic entry. Thiothixene was developed decades ago, and the branded product has lost the market exclusivity associated with its original approval.

The relevant protection analysis is therefore formulation-specific rather than molecule-specific.

Protection category	Commercial relevance
Composition-of-matter patent	Expired or commercially obsolete
Original product patent	Expired or commercially obsolete
FDA marketing exclusivity	No current meaningful exclusivity expected for the established capsule product
Capsule formulation patents	Must be assessed at the applicant and product level
Method-of-use patents	Limited practical value for the established schizophrenia indication unless tied to a new formulation or patient population
Manufacturing patents	Potentially relevant for a new process, impurity-control method, or solid-state form
Trademark protection	Brand recognition for Navane is not a meaningful barrier to generic substitution

The FDA Orange Book remains the controlling source for listed patents and exclusivity associated with approved products.[3] A prospective applicant should distinguish between expired patents, unlisted historical patents, and any patents associated with a newly approved reformulation.

When does thiothixene lose exclusivity?

Thiothixene's original market exclusivity has already expired. Standard capsule products compete through ANDA approval, abbreviated labeling, manufacturing reliability, pricing, and pharmacy availability.

A new thiothixene product could create a fresh regulatory and patent position if it uses a materially different dosage form or delivery system. Potential examples include:

• Oral solution or concentrate
• Orally disintegrating tablet
• Multiparticulate capsule
• Sprinkle formulation
• Modified-release product
• Long-acting injectable
• Fixed-dose combination
• Formulation designed for patients with swallowing difficulty

The regulatory route would depend on the degree of difference from the reference product. A substantially equivalent capsule could use an ANDA. A new dosage form, route, strength, excipient system, or clinical claim could require a 505(b)(2) application.[4]

What excipients are used in generic thiothixene capsules?

Excipient composition varies by manufacturer and strength. U.S. labels and DailyMed entries should be used to confirm each marketed product's inactive ingredients.[1,5]

Common capsule design elements may include:

• Lactose or another filler
• Pregelatinized starch or starch-based disintegrant
• Magnesium stearate or another lubricant
• Colloidal silicon dioxide
• Gelatin capsule shells
• Titanium dioxide
• Iron oxides or other colorants
• Pharmaceutical ink

The practical formulation objective is not simply to reproduce a low-cost capsule. It is to maintain content uniformity at low strengths, control powder flow, limit degradation, and avoid excipients that create avoidable switching or tolerability problems.

What excipient risks matter for thiothixene?

Thiothixene has a low-dose strength range, which makes blend uniformity and segregation important. A formulation designed around a high-dose drug may not scale reliably to the 1 mg or 2 mg capsules.

Key risks include:

1. Low-dose content uniformity. Small quantities of thiothixene hydrochloride require controlled particle-size distribution, geometric dilution, and validated blending.

2. Moisture sensitivity. Hygroscopic excipients can alter powder flow, capsule fill weight, dissolution, and stability.

3. Colorant variability. Colorants create unnecessary supplier qualification and may cause patient or institutional preference issues.

4. Lactose intolerance and excipient avoidance. Lactose-free positioning may be commercially useful in hospitals, long-term-care settings, and patients who already manage multiple medications.

5. Gelatin dependence. Vegetarian, religious, and institutional purchasing requirements can support a non-gelatin capsule, although the alternative shell must maintain mechanical strength and dissolution performance.

6. Magnesium stearate over-lubrication. Excessive lubrication can reduce wettability and slow dissolution, particularly in low-dose blends.

7. Capsule-shell performance. HPMC or pullulan shells can support non-animal positioning but may require different filling, storage, and dissolution controls.

What formulation patents could protect a new thiothixene product?

A new formulation would need a defensible technical feature and measurable clinical or manufacturing value. A generic capsule with routine excipient substitution is unlikely to create a strong commercial moat.

Potential patentable areas include:

Formulation area	Possible claim focus	Commercial value
Low-dose blend	Uniformity across 1 mg and 2 mg strengths	Reduces manufacturing failure risk
Taste-masked liquid	Suspension, solution, or multiparticulate system	Supports patients unable to swallow capsules
Orally disintegrating tablet	Rapid dispersion without water	Adherence and administration benefit
Sprinkle capsule	Pellets or granules for soft food	Long-term-care and swallowing-difficulty use
Modified release	Controlled exposure or reduced dosing frequency	Potentially high value but clinically demanding
Long-acting injectable	Depot particle or oil-based system	Highest differentiation, highest development cost
Excipient-minimized capsule	Lactose-free, dye-free, or gelatin-free composition	Procurement and patient-preference advantage
Impurity-control process	Reduced degradants or improved shelf life	Supports manufacturing and regulatory differentiation

Patent claims should focus on composition ranges, particle engineering, dissolution profiles, stability, and process parameters. Broad claims covering routine capsule excipient substitutions would face validity and obviousness challenges.

How strong is the thiothixene patent estate?

The estate is weak for conventional immediate-release capsules and potentially stronger for a genuinely differentiated delivery system.

Conventional capsule

The standard capsule opportunity is commercially accessible but difficult to scale profitably. FDA approval, supply continuity, and low-cost manufacturing matter more than patent exclusion. A new capsule patent would likely provide limited value unless it solved a documented problem such as low-dose uniformity, impurity growth, or shelf-life failure.

New oral formulation

An oral solution, ODT, or sprinkle product could support a 505(b)(2) strategy and formulation patents. The strength of the position would depend on:

• Demonstrated clinical or administration benefit
• Distinctive dissolution or absorption profile
• Non-obvious excipient combination
• Patent term remaining at approval
• Ability to obtain product-specific labeling
• Payer willingness to reimburse a premium

Long-acting injectable

A depot product could create the strongest differentiated position. It would also require extensive formulation, pharmacokinetic, local-tolerance, and clinical work. Thiothixene's limited current market may not support the investment unless a developer identifies a defined population with poor adherence and limited treatment alternatives.

Are there Paragraph IV challenges for thiothixene?

Paragraph IV litigation is most relevant when an ANDA applicant certifies that a listed patent is invalid, unenforceable, or not infringed. For an old generic product with no material active Orange Book patent barrier, ordinary thiothixene capsules are more likely to proceed through routine ANDA certification than through high-value Paragraph IV litigation.[3,6]

A Paragraph IV dispute could arise if a company obtains approval for a new thiothixene formulation and lists patents covering that product. The likely dispute would concern:

• Whether the generic reproduces the claimed excipient ranges
• Whether a formulation claim is obvious
• Whether a process claim is infringed
• Whether the patent is properly listed in the Orange Book
• Whether the proposed label induces infringement of a patented method of use

What is the Orange Book status of thiothixene?

The Orange Book identifies FDA-approved products, therapeutic-equivalence information, listed patents, and exclusivity where applicable.[3] Established generic thiothixene capsules are generally evaluated as multisource products rather than protected branded products.

For commercial diligence, the relevant checks are:

1. Current active listings for thiothixene hydrochloride capsules.
2. Strength-by-strength availability.
3. Therapeutic-equivalence codes.
4. Any listed patent associated with a current product.
5. Discontinued-product status.
6. Applicant and manufacturing-site concentration.
7. FDA approval history and labeling differences.

Orange Book status should be checked before filing because a reformulated product may have a different listing profile from the legacy capsule.

What regulatory pathways are available for thiothixene?

505(j) ANDA

An ANDA is appropriate for a product that matches the reference product in active ingredient, dosage form, route, strength, labeling framework, and therapeutic equivalence requirements. This route offers the lowest development burden but also the lowest differentiation.

505(b)(2)

A 505(b)(2) application may be appropriate for a new thiothixene dosage form, route, formulation, or dosing regimen that relies partly on FDA findings for an approved product.[4] It can support product-specific labeling and may create a stronger commercial position, but it may require additional clinical or pharmacokinetic evidence.

New drug application

A full NDA would be relevant only if the sponsor seeks a substantial new clinical profile or develops a product that cannot rely adequately on existing findings.

Thiothixene is a small-molecule drug, so biosimilar regulations do not apply. A developer instead faces generic-equivalence, reformulation, or full-drug-development requirements.

What commercial opportunities exist for thiothixene excipients?

1. Excipient-minimized generic capsule

A lactose-free, dye-free, gelatin-free capsule could target hospitals, long-term-care facilities, and specialty pharmacies. The product would need a procurement rationale beyond patient preference, such as fewer formulation restrictions and consistent supply.

2. Sprinkle formulation

A capsule containing coated granules or pellets that can be administered with soft food could address dysphagia and adherence problems. The design must prevent crushing-related exposure changes and maintain dose uniformity after opening.

3. Oral liquid

An oral solution or suspension could support patients who cannot swallow solid dosage forms. The main development risks are solubility, chemical stability, sedimentation, preservative performance, palatability, and accurate dosing at low concentrations.

4. Orally disintegrating tablet

An ODT could improve administration in supervised-care settings. Taste masking is central because an ODT increases oral exposure to the drug before swallowing. The excipient system may use mannitol, crospovidone, low-substituted hydroxypropyl cellulose, or similar platform materials, subject to compatibility and dissolution testing.

5. Contract manufacturing and supply continuity

Because old generic products can experience intermittent shortages or manufacturer exits, a dependable supplier can win institutional business without owning a major patent position. FDA Drug Shortages data and product availability should be monitored when evaluating this strategy.[7]

6. Platform licensing

A developer with a validated ODT, sprinkle, liquid, or depot platform could license the technology to a generic manufacturer or specialty pharmaceutical company. The most credible deal structure would combine:

• Upfront technology fee
• Development milestones
• Regulatory milestone payment
• Royalties on net sales
• Manufacturing or territory rights
• Access to analytical and stability packages

What manufacturing and intellectual-property barriers exist?

The principal manufacturing barriers are technical rather than patent-based.

Low-dose content uniformity is the central capsule risk. Drug particle engineering, premixing, blend validation, capsule-filling accuracy, and segregation control must be aligned across all strengths.

A liquid product introduces solubility and stability barriers. A depot product adds particle-size control, sterilization, injectability, release kinetics, and local tolerability.

Geographic protection would likely be strongest in the United States, Europe, Japan, and other jurisdictions with established generic pathways. Patent value outside those markets depends on local filing dates, patent-term adjustments, national examination, and whether the product has meaningful reimbursement.

What litigation and settlement issues affect thiothixene?

There is no obvious basis for assuming active, high-value litigation around the legacy thiothixene capsule market. Any material dispute is more likely to involve a newly approved reformulation, manufacturing process, or supply agreement.

Potential litigation categories include:

• ANDA patent litigation for a reformulated product
• Trade-secret claims involving manufacturing processes
• Contract disputes over territory or supply
• Product-liability litigation involving antipsychotic adverse effects
• Hatch-Waxman disputes over patent listing or notice
• Labeling disputes concerning method-of-use claims

Settlement value would be limited for an old generic capsule unless the product had a protected formulation, a supply shortage, or a specialized institutional market.

How does thiothixene compare with competing antipsychotics?

Product	Market position	Formulation opportunity	Competitive pressure
Thiothixene	Legacy typical antipsychotic	ODT, liquid, sprinkle, excipient-minimized capsule	Low commercial scale
Haloperidol	Widely used typical antipsychotic	Oral liquid, injectable, depot	Stronger hospital presence
Fluphenazine	Typical antipsychotic	Oral and depot products	Depot competes directly on adherence
Perphenazine	Typical antipsychotic	Oral dosage-form differentiation	Generic price pressure
Risperidone	Atypical antipsychotic	ODT, liquid, long-acting injectable	Much broader commercial demand
Olanzapine	Atypical antipsychotic	ODT and injectable	Stronger prescribing base
Quetiapine	Atypical antipsychotic	Immediate- and extended-release products	Higher volume and broader use

Thiothixene's best opportunity is a narrow, execution-focused product that solves administration or supply problems. A broad premium-brand strategy is difficult to justify because competing antipsychotics have stronger clinical familiarity and larger commercial markets.

What revenue exposure and launch scenarios exist?

Public revenue data for generic thiothixene are generally limited because sales are reported within broader generic portfolios. The market should be modeled through units, average selling price, customer concentration, and shortage-driven price volatility rather than branded peak-sales assumptions.

Launch scenario	Development burden	Pricing potential	Commercial outlook
Standard generic capsule	Low to moderate	Low	Viable only with efficient manufacturing
Lactose-free or dye-free capsule	Moderate	Low to moderate	Niche institutional opportunity
Sprinkle capsule	Moderate to high	Moderate	Attractive for dysphagia and long-term care
Oral liquid	High	Moderate	Useful specialty opportunity
ODT	High	Moderate to high	Requires taste and adherence advantage
Long-acting injectable	Very high	High	Potentially differentiated but economically uncertain

Key Takeaways

• Thiothixene's original molecule and brand protections do not create a meaningful barrier to ordinary generic entry.
• The commercial value lies in formulation differentiation, supply reliability, and institutional procurement.
• Low-dose content uniformity is the most important capsule-development issue.
• Lactose-free, dye-free, gelatin-free, sprinkle, liquid, and ODT products offer the clearest excipient-led opportunities.
• A conventional capsule is likely to be a low-margin business unless manufacturing costs and supply reliability are superior.
• A 505(b)(2) strategy may support new dosage forms, but it requires stronger evidence and a clear clinical or administration benefit.
• Thiothixene is not subject to biosimilar competition.
• New formulation patents may have value, but routine excipient substitutions are unlikely to create durable exclusivity.
• Revenue should be modeled as a specialty generic opportunity, not as a branded antipsychotic franchise.

FAQs

Can thiothixene be formulated without lactose?

Yes. A lactose-free capsule can use alternative fillers such as microcrystalline cellulose, mannitol, starch derivatives, or other suitable excipients. The sponsor must demonstrate content uniformity, dissolution, stability, and bioequivalence where required.

Is an orally disintegrating thiothixene tablet commercially attractive?

Potentially, but the product would need a clear administration advantage. Taste masking, dose uniformity, mechanical strength, moisture control, and reimbursement would determine commercial viability.

Does thiothixene have biosimilar risk?

No. Thiothixene is a small-molecule drug. Competitive products are generics or reformulations regulated through ANDA, 505(b)(2), or NDA pathways.

Could a thiothixene liquid obtain new exclusivity?

A liquid formulation could potentially receive product-specific patents and regulatory exclusivity tied to the new product, depending on the application and claims. It would not restore exclusivity to the old capsule product.

Which thiothixene product has the strongest commercial differentiation?

A sprinkle formulation or long-acting injectable would have the highest potential differentiation. The sprinkle product has a more manageable development burden, while the injectable offers greater differentiation but substantially higher clinical and manufacturing risk.

References

1. DailyMed. (n.d.). Thiothixene hydrochloride capsule prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (2022). Applications covered by section 505(b)(2). https://www.fda.gov/drugs/development-resources/applications-covered-section-505b2

5. U.S. National Library of Medicine. (n.d.). DailyMed. https://dailymed.nlm.nih.gov/dailymed/

6. U.S. Food and Drug Administration. (n.d.). Paragraph IV drug product applications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/paragraph-iv-drug-product-applications

7. U.S. Food and Drug Administration. (n.d.). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages